Antiplatelet Effects in Stroke-Patients

Dipyrone Nullifies Aspirin Antiplatelet Effects in Stroke-Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02148939

Enrollment

Registered

2014-05-29

Start date

2014-05-31

Completion date

2015-02-28

Last updated

2015-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke

Keywords

ischemic stroke, Antiplatelet Effects, aspirin, metamizole, dipyrone

Brief summary

Many patients suffer from acute and chronic pain. The incidence of chronic pain correlates with increased age. Most of patients rely on analgesic medication to control the pain. Dipyrone is an extensively used drug in Western and Eastern Europe as well as Central and South America, largely due to its favorable analgesic and antipyretic effects in conjunction with a low incidence of gastrointestinal complications when compared to other non-steroidal anti-inflammatory drugs (NSAIDs). Aspirin is the backbone of antiplatelet therapy in patients after ischemic stroke. However, it is known that there are substantial inter-individual response variabilities to antiplatelet medication. Furthermore, patients with impaired response to aspirin have a significant higher risk of recurrent cerebrovascular events. The investigators have recently shown that co-medication with aspirin and dipyrone in patients with coronary artery disease lead to insufficient antiplatelet effects of aspirin. The incidence of chronic pain is very high in patients with ischemic stroke. Therefore, in this study the investigators aim to examine, if co-medication of aspirin and dipyrone interaction also occurs in patients after ischemic stroke.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 18 years * Patients with ischemic stroke and ASS-medication (80-320 mg/day) with/without analgesic comedication

Exclusion criteria

* Reanimation * cardiogenic shock

Design outcomes

Primary

Measure	Time frame
Laboratory response to aspirin therapy in metamizole co-medicated Stroke patients	Baseline

Secondary

Measure	Time frame
Major adverse cardiac and cerebrovascular events (MACCE Events) during hospital stay	participants are followed until discharge up to 4 weeks

Countries

Germany

Outcome results